N
Nelson B. Watts
Researcher at University of Cincinnati Academic Health Center
Publications - 215
Citations - 20940
Nelson B. Watts is an academic researcher from University of Cincinnati Academic Health Center. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 59, co-authored 209 publications receiving 18999 citations. Previous affiliations of Nelson B. Watts include Emory University & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years
Nelson B. Watts,John T. Grbic,Neil Binkley,S. Papapoulos,Peter W. Butler,Xiang Yin,Antoniette Tierney,Rachel B. Wagman,Michael R. McClung +8 more
TL;DR: Although invasive OPEs were common in these denosumab-treated women and were associated with an increased ONJ incidence, the overall rate of ONJ was low, and all cases with complete follow-up resolved with treatment.
Journal ArticleDOI
Standards and guidelines for performing central dual X-ray densitometry from the Canadian panel of International Society for Clinical Densitometry.
Aliya Khan,Jacques P. Brown,Kenneth G. Faulkner,David L. Kendler,Brian C. Lentle,William D. Leslie,Paul D. Miller,L. Nicholson,Wojciech P. Olszynski,Nelson B. Watts,David A. Hanley,Anthony B. Hodsman,Robert G. Josse,Timothy M. Murray,K. Yuen +14 more
TL;DR: This article focuses on central dual X-ray absorptiometry in adults and does not address densitometry in the pediatric population.
Journal ArticleDOI
Risk factors for kidney stones in older women in the southern United States.
W. Dallas Hall,Nelson B. Watts,Mary Pettinger,A.L. Oberman,Karen C. Johnson,Electra D. Paskett,Marian C. Limacher,Jennifer Hays +7 more
TL;DR: Multivariate risk factors for the occurrence of kidney stones in postmenopausal women include a history of hypertension, a low dietary intake of magnesium, and low use of calcium supplements.
Journal ArticleDOI
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
James A. Simon,Ayman Al-Hendy,David F. Archer,Kurt T. Barnhart,Linda D. Bradley,Bruce R. Carr,Thomas Dayspring,Eve C. Feinberg,Veronica Gillispie,Sandra Hurtado,Jin Hee Kim,Ran Liu,Charlotte D. Owens,Ozgul Muneyyirci-Delale,Alice Wang,Nelson B. Watts,William D. Schlaff +16 more
TL;DR: Up to 12 months of elagolix with add-back therapy provided sustained reduction in menstrual blood loss with an acceptable safety profile in women with uterine leiomyomas.
Journal Article
The 2002 Canadian bone densitometry recommendations: take-home messages
Aliya Khan,Jacques P. Brown,David L. Kendler,William D. Leslie,Brian C. Lentle,E. Michael Lewiecki,Paul D. Miller,R. Lawrence Nicholson,Wojciech P. Olszynski,Nelson B. Watts +9 more
TL;DR: A 59-year-old woman asks her family physician about her risk of osteoporosis and fractures after experiencing a radial fracture from a fall earlier this year and has no family history of fractures.